Linking in vitro and ex vivo CB<sub>1</sub> activity with serum concentrations and clinical features in 5F-MDMB-PICA users to better understand SCRAs and their metabolites.

Janssens, Liesl K; Hudson, Simon; Wood, David M; Wolfe, Caitlin; Dargan, Paul I; Stove, Christophe P

Linking in vitro and ex vivo CB₁ activity with serum concentrations and clinical features in 5F-MDMB-PICA users to better understand SCRAs and their metabolites.

Janssens, Liesl K; Hudson, Simon; Wood, David M; Wolfe, Caitlin; Dargan, Paul I; Stove, Christophe P.

Afiliação

Janssens LK; Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Hudson S; LGC Ltd- Sport and Specialised Analytical Services, Cambridge, UK.
Wood DM; Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Wolfe C; Faculty of Life Sciences and Medicine, King's College London, London, UK.
Dargan PI; Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Stove CP; Department of Emergency Medicine, Dalhousie University, Halifax, Canada.

Arch Toxicol ; 96(11): 2935-2945, 2022 11.

Article em En | MEDLINE | ID: mdl-35962200

Assuntos

Canabinoides; Drogas Ilícitas; Agonistas de Receptores de Canabinoides/farmacologia; Canabinoides/metabolismo; Humanos; Drogas Ilícitas/química; Receptor CB1 de Canabinoide; Receptores de Canabinoides

Palavras-chave

Activity-based; Bioassay; Characterization; Clinical toxicology; LC-HRMS; NPS

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canabinoides / Drogas Ilícitas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Arch Toxicol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google